{
    "balance": {
        "data": [
            "CONSOLIDATED BALANCE SHEETS\tDollars in Millions\t(UNAUDITED)\tASSETS\tMarch 31,\t2020\tDecember 31,\t2019\tCurrent Assets:\tCash and cash equivalents\t$\t15,817\t$\t12,346\tMarketable debt securities\t2,505\t3,047\tReceivables\t8,290\t7,685\tInventories\t2,836\t4,293\tOther current assets\t2,405\t1,983\tTotal Current Assets\t31,853\t29,354\tProperty, plant and equipment\t6,112\t6,252\tGoodwill\t22,452\t22,488\tOther intangible assets\t61,666\t63,969\tDeferred income taxes\t605\t510\tMarketable debt securities\t651\t767\tOther non-current assets\t5,946\t6,604\tTotal Assets\t$\t129,285\t$\t129,944\tLIABILITIES\tCurrent Liabilities:\tShort-term debt obligations\t$\t3,862\t$\t3,346\tAccounts payable\t3,069\t2,445\tOther current liabilities\t12,301\t12,513\tTotal Current Liabilities\t19,232\t18,304\tDeferred income taxes\t6,531\t6,454\tLong-term debt\t42,844\t43,387\tOther non-current liabilities\t10,701\t10,101\tTotal Liabilities\t79,308\t78,246\tCommitments and contingencies\tEQUITY\tBristol-Myers Squibb Company Shareholders  Equity:\tPreferred stock\t \t \tCommon stock\t292\t292\tCapital in excess of par value of stock\t43,254\t43,709\tAccumulated other comprehensive loss\t(\t1,549\t)\t(\t1,520\t)\tRetained earnings\t32,671\t34,474\tLess cost of treasury stock\t(\t24,757\t)\t(\t25,357\t)\tTotal Bristol-Myers Squibb Company Shareholders  Equity\t49,911\t51,598\tNoncontrolling interest\t66\t100\tTotal Equity\t49,977\t51,698\tTotal Liabilities and Equity\t$\t129,285\t$\t129,944\tThe accompanying notes are an integral part of these consolidated financial statements.\t4\tBRISTOL-MYERS SQUIBB COMPANY\tCONSOLIDATED STATEMENTS OF CASH FLOWS\tDollars in Millions\t(UNAUDITED)\tThree Months Ended March 31,\t2020\t2019\tCash Flows From Operating Activities:\tNet (loss)/earnings\t$\t(\t766\t)\t$\t1,715\tAdjustments to reconcile net (loss)/earnings to net cash provided by operating activities:\tDepreciation and amortization, net\t2,477\t170\tDeferred income taxes\t(\t53\t)\t78\tStock-based compensation\t210\t53\tImpairment charges\t53\t45\tPension settlements and amortization\t11\t66\tDivestiture gains and royalties\t(\t173\t)\t(\t166\t)\tEquity investment losses/(gains)\t339\t(\t175\t)\tContingent consideration fair value adjustments\t556\t \tOther adjustments\t(\t42\t)\t(\t6\t)\tChanges in operating assets and liabilities:\tReceivables\t(\t743\t)\t236\tInventories\t1,448\t35\tAccounts payable\t703\t136\tIncome taxes payable\t229\t120\tOther\t(\t355\t)\t(\t917\t)\tNet Cash Provided by Operating Activities\t3,894\t1,390\tCash Flows From Investing Activities:\tSale and maturities of marketable debt securities\t1,394\t1,211\tPurchase of marketable debt securities\t(\t735\t)\t(\t242\t)\tCapital expenditures\t(\t186\t)\t(\t204\t)\tDivestiture and other proceeds\t205\t310\tAcquisition and other payments, net of cash acquired\t(\t25\t)\t(\t15\t)\tNet Cash Provided by Investing Activities\t653\t1,060\tCash Flows From Financing Activities:\tShort-term debt obligations, net\t26\t(\t73\t)\tRepayment of long-term debt\t \t(\t1,250\t)\tRepurchase of common stock\t(\t81\t)\t \tDividends\t(\t1,017\t)\t(\t669\t)\tOther\t18\t(\t37\t)\tNet Cash Used in Financing Activities\t(\t1,054\t)\t(\t2,029\t)\tEffect of Exchange Rates on Cash, Cash Equiv"
        ],
        "timestamp": "2025-01-21_09-31-24"
    }
}